CoChat

Three‐Year Safety Results of SAR422459 (EIAV‐ABCA4) Gene Therapy in Patients With ABCA4‐Associated Stargardt Disease: An Open‐Label Dose‐Escalation Phase I/IIa Clinical Trial, Cohorts 1‐5

Open access
Parker, Maria A., Erker, Laura R., Audo, Isabelle, Choi, Dongseok, Mohand-Said, Saddek, Sestakauskas, Kastytis, Benoit, Patrick, Appelqvist, Terence, Krahmer, Melissa, Ségaut-Prévost, Caroline, Lujan, Brandon J., Faridi, Ambar, Chegarnov, Elvira N., Steinkamp, Peter N., Ku, Cristy, da Palma, Mariana Matioli, Barale, Pierre-Olivier, Ayelo-Scheer, Sarah, Lauer, Andreas, Stout, Tim, Wilson, David J., Weleber, Richard G., Pennesi, Mark E., Sahel, José Alain, Yang, Paul · 2022 · American Journal of Ophthalmology
Cited by 60

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

PURPOSE: To report on the safety of the first 5 cohorts of a gene therapy trial using recombinant equine infectious anemia virus expressing ABCA4 (EIAV-ABCA4) in adults with Stargardt dystrophy due to mutations in ABCA4. DESIGN: Nonrandomized multicenter phase I/IIa clinical trial. METHODS: Patients received a subretinal injection of EIAVABCA4 in the worse-seeing eye at 3 dose levels and were followed for 3 years after treatment. MAIN OUTCOME MEASURES: The primary end point was ocular and systemic adverse events. The secondary end points were best-corrected visual acuity, static perimetry, kinetic perimetry, total field hill of vision, full field electroretinogram, multifocal ERG, color fundus photography, short-wavelength fundus autofluorescence, and spectral domain optical coherence tomography. RESULTS: The subretinal injections were well tolerated by all 22 patients across 3 dose levels. There was 1 case of a treatment-related ophthalmic serious adverse event in the form of chronic ocular hypertension. The most common adverse events were associated with the surgical procedure. In 1 patient treated with the highest dose, there was a significant decline in the number of macular flecks as compared with the untreated eye. However, in 6 patients, hypoautofluorescent changes were worse in the treated eye than in the untreated eye. Of these, 1 patient had retinal pigment epithelium atrophy that was characteristic of tissue damage likely associated with bleb induction. No patients had any clinically significant changes in best-corrected visual acuity, static perimetry, kinetic perimetry, total field hill of vision, full field electroretinogram, or multifocal ERG attributable to the treatment. CONCLUSIONS: Subretinal treatment with EIAV-ABCA4 was well tolerated with only 1 case of ocular hypertension. No clinically significant changes in visual function tests were found to be attributable to the treatment. However, 27% of treated eyes showed exacerbation of retinal pigment epithelium atrophy on fundus autofluorescence. There was a significant reduction in macular flecks in 1 treated eye from the highest dose cohort. Additional follow-up and continued investigation in more patients will be required to fully characterize the safety and efficacy of EIAV-ABCA4.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ajo.2022.02.013

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 60

Metadata

Authors
Parker, M. A., Erker, L. R., Audo, I., Choi, D., Mohand-Said, S., Sestakauskas, K., Benoit, P., Appelqvist, T., Krahmer, M., Ségaut-Prévost, C., Lujan, B. J., Faridi, A., Chegarnov, E. N., Steinkamp, P. N., Ku, C., da Palma, M. M., Barale, P.-O., Ayelo-Scheer, S., Lauer, A., Stout, T., Wilson, D. J., Weleber, R. G., Pennesi, M. E., Sahel, J. A., & Yang, P.
Venue
American Journal of Ophthalmology
Publisher
Elsevier BV
Published
2022-08
Volume
240
Pages
285-301
ISSN
0002-9394 (ISSN-L)
OpenAlex
W4214952103
Cited by
60
References
14
FWCI
3.59
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Three‐Year Safety Results of SAR422459 (EIAV‐ABCA4) Gene Therapy in Patients With ABCA4‐Associated Stargardt Disease: An Open‐Label Dose‐Escalation Phase I/IIa Clinical Trial, Cohorts 1‐5. https://app.cochat.ai/papers/10.1016/j.ajo.2022.02.013
The paper
Parker, M. A., Erker, L. R., Audo, I., Choi, D., Mohand-Said, S., Sestakauskas, K., Benoit, P., Appelqvist, T., Krahmer, M., Ségaut-Prévost, C., Lujan, B. J., Faridi, A., Chegarnov, E. N., Steinkamp, P. N., Ku, C., da Palma, M. M., Barale, P.-O., Ayelo-Scheer, S., Lauer, A., . . . Yang, P. (2022). Three‐Year Safety Results of SAR422459 (EIAV‐ABCA4) Gene Therapy in Patients With ABCA4‐Associated Stargardt Disease: An Open‐Label Dose‐Escalation Phase I/IIa Clinical Trial, Cohorts 1‐5. American Journal of Ophthalmology. https://doi.org/10.1016/j.ajo.2022.02.013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.